The anti-Jo-1 syndrome A specific form of myositis with interstitial lung disease;Das Anti-Jo-1-Syndrom eine Sonderform der Myositis mit interstitieller Lungenerkrankung

Pneumologie

Volumn 64, Issue 8, 2010, Pages 496-503

  Haussermann A ^a   Gillissen, A ^a   Seidel, W ^b  

^a Robert Koch Klinik   (Germany)

^b Klinikum St Georg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE TRANSFER RNA LIGASE; AZATHIOPRINE; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FRUCTOSE BISPHOSPHATE ALDOLASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOCORTICOID; GLYCINE TRANSFER RNA LIGASE; HISTIDINE TRANSFER RNA LIGASE; IMMUNOSUPPRESSIVE AGENT; JO 1 ANTIBODY; LACTATE DEHYDROGENASE; METHOTREXATE; PHENYLALANINE TRANSFER RNA LIGASE; PREDNISOLONE; THREONINE TRANSFER RNA LIGASE; TYROSINE TRANSFER RNA LIGASE;

ANTI JO 1 SYNDROME; ANTIBODY PRODUCTION; ARTHRALGIA; AUTOIMMUNE DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSPNEA; FEVER; HUMAN; IMMUNOHISTOLOGY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG FUNCTION TEST; LUNG INFILTRATE; MYOSITIS; POLYARTHRITIS; POLYMYOSITIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; SKIN DEFECT; SYMPTOMATOLOGY; T LYMPHOCYTE; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINUCLEAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MYOSITIS; SYNDROME;

EID: 77955508194     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0029-1244054     Document Type: Review

References (102)

1. Mills E S., Mathews W H. Interstitial pneumonitis in dermatomyositis. JAMA 1956 160 1467-1470
2. Broich P, Jerusalem F. Polymyositis, Dermatomyositis und andere entzündliche Muskelerkrankungen. In: Miehle W, Fehr K, Schattenkirchner M, Tillmann K, Hrsg. Rheumatologie in Praxis und Klinik. 2. Aufl. Stuttgart Thieme 2000
3. Váncsa A, Csípö I, Németh J et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009 29 989-994
4. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthitis Rheum 1980 23 881-888
5. Yoshida S, Akizuki M, Mimori T et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases: a marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983 26 604-611
6. Marguerie C, Bunn C C., Beynon H L. et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990 77 1019-1038
7. Dickey B F., Myers A R. Pulmonary disease in polymyositis/ dermatomyositis. Semin Arthritis Rheum 1984 14 60-76
8. Benbassat J, Gefel D, Larholt K et al. Prognostic factors in polymyositis/dermatomyositis: a computer-assisted analysis of ninety-two cases. Arthritis Rheum 1985 28 249-255
9. Marie I, Hachulla E, Cherin P et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002 47 614-622
10. Marie I, Hachulla E, Cherin P et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005 53 155-165
11. Dankó K, Ponyi A, Constantin T et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004 83 35-42
12. Hengstman G J., van Venrooij W J., Vencovsky J et al. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis 2000 59 141-142
13. Weitoft T. Occurrence of polymyositis in the county of Gavleborg, Sweden. Scand J Rheumatol 1997 26 104-106
14. Fathi M, Lundberg I E. Interstitial lung disease in polymyositis and dermatomyositis. Current Opinion in Rheumatology 2005 17 701-706
15. Rutjes S A., Vree Egberts W T., Jongen P et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997 109 32-40
16. Fox S A., Ward B K., Robbins P D. et al. Inclusion body myositis: investigation of the mumps virus hypothesis by polymerase chain reaction. Muscle Nerve 1996 19 23-28
17. Leff R L., Love L A., Miller F W. et al. Viruses in idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992 339 1192-1195
18. Friedman J M., Pachman L M., Maryjowski M L. et al. Immunogenetic studies of juvenile dermatomyositis: HLADR antigen frequencies. Arthritis Rheum 1983 26 214-216
19. OHanlon T P., Carrick D M., Arnett F C. et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -DRB1 allelic profiles and motifs define clinicopathologic groups in Caucasians. Medicine 2005 84 338-349
20. Chinoy H, Salway F, Fertig N et al. The UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC). In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006 8 R13
21. Love L A., Leff R L., Fraser D D. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine Baltimore 1991 70 360-374
22. Love L A., Miller F W. Noninfectious environmental agents associated with myopathies. Curr Opin Rheum 1993 5 712-718
23. Bohan A, Peter J B. Polymyositis and dermatomyositis. N Engl J Med 1975 292 344-347
24. Targoff I N. Immune manifestation of inflammatory muscle disease. Dis Clin North Am 1994 20 857-880
25. Selva-OCallaghan A, Labrador-Horrillo M, Solans-Laque R et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006 55 791-798
26. Fathi M, Dastmalchi M, Rasmussen E et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 2004 63 297-301 (Pubitemid 38250674)
27. La Corte R, Lo Mo Naco A, Locaputo A et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006 39 249-253
28. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 2005 38 383-392
29. Dalakas M C. Polymyositis and dermatomyositis. Lancet 2003 362 971-982
30. Chen I-J, Wu Y-J, Lin C-W et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009 28 639-646
31. Rider L G., Miller F W. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995 2 1-9
32. Kalluri M, Sahn S A., Oddis C V. et al. Clinical Profile of Anti-PL-12 Autoantibody. Chest 2009 135 1550-1556
33. Arahata K, Engel A G. Monoclonal antibody analysis of mononuclear cells in myopathies: I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984 16 193-208
34. Engel A G., Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies, II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984 16 209-215
35. Mimori T, Imura Y, Nakashima R et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007 19 523-529
36. Bernstein R M., Morgan S H., Chapman J et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. BMJ Clin Res Ed 1984 289 151-152
37. Schmidt W A., Wetzel W, Friedlander R et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies: an evolving spectrum of disease manifestations. Clin Rheumatol 2000 19 371-377
38. Hengstman G J., van Engelen B G., van Venrooij W J. Myositis-specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004 16 692-699
39. Miller F W. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993 270 1846-1849
40. Schwarz M I. The lung in polymyositis. Clin Chest Med 1998 19 701-712
41. Schnabel A, Reuter M, Biederer J et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003 32 273-284
42. Frazier A R., Miller R D. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 1974 65 403-407
43. Kang E H., Lee E B., Shin K C. et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology Oxford 2005 44 1282-1286
44. Oddis C V., Medsger T A., Cooperstein L A. A subluxing arthropathy associated with the Anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum 1990 33 1640-1645
45. Schumacher H R., Schimmer B, Gordon G V. et al. Articular manifestations of polymyositis and dermatomyositis. Amer J Med 1979 67 287-292
46. Taylor A J., Wortham D C., Burge J R., Rogan K M. The heart in polymyositis: a prospective evaluation of 26 patients. Clin Cardiol 1993 16 802-808
47. Bohan A, Peter J B. Polymyositis and dermatomyositis. N Engl J Med 1975 292 403-407
48. Tanimoto K, Nakano K, Kano S et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995 22 668-674
49. Fathi M, Lundberg I E., Tornling G. Pulmonary Complications of Polymyositis and Dermatomyositis. Semin Respir Crit Care Med 2007 28 451-458
50. Epler G R., McLoud T C., Gaensler E A. et al. Normal chest roentgenograms in chronic diffuse infiltrative lung disease. N Engl J Med 1978 298 934-939
51. Muller N L., Staples C A., Miller R R. et al. Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 1987 165 731-734
52. Muller N L., Miller R R., Webb W R. et al. Fibrosing alveolitis: CT-pathologic correlation. Radiology 1986 160 585-588
53. Nishimura K, Kitaichi M, Izumi T et al. Usual interstitial pneumonia: histologic correlation with high-resolution CT. Radiology 1992 182 337-342
54. Bonnefoy O, Ferretti G, Calaque O et al. Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. Eur J Radiol 2004 49 235-244
55. Lee C S., Chen T L., Tzen C Y. et al. Idiopathic inflammatory myopathy with diffuse alveolar damage. Clin Rheumatol 2002 21 391-396
56. Arakawa H, Yamada H, Kurihara Y et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003 123 1096-1103
57. Remy-Jardin M, Giraud F, Remy J et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology 1993 189 693-698
58. Yang Y, Fujita J, Tokuda M et al. Chronological evaluation of the onset of histologically confirmed interstitial pneumonia associated with polymyositis/dermatomyositis. Intern Med 2002 41 1135-1141
59. Wallaert B, Hatron P Y., Grosbois J M. et al. Subclinical pulmonary involvement in collagenvascular diseases assessed by bronchoalveolar lavage: relationship between alveolitis and subsequent changes in lung function. Am Rev Respir Dis 1986 133 574-580
60. Tazelaar H D., Viggiano R W., Pickersgill J et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990 141 727-733
61. Bjoraker J A., Ryu J H., Edwin M K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998 157 199-203
62. Douglas W W., Tazelaar H D., Hartman T E. et al. Polymyositis- Dermatomyositis associated interstitial lung disease. Am J Respir Crit Care Med 2001 164 1182-1185
63. Tansey D, Wells A U., Colby T V. et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. histopathology 2004 44 585-596
64. Bohlmeyer T J., Wu A HB, Perryman M B. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin N Amer 1994 20 240-250
65. Bernstein R M. Autoantibodies in myositis. Baillières clin Neurol 1993 2 599-615
66. Tillie-Leblond I, Wislez M, Valeyre D et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008 63 53-59
67. Zampieri S, Ghirardello A, Iaccarino L et al. Anti-jo-1 antibodies. Autoimmunity 2005 38 73-78
68. Kubo M, Ihn H, Yamane K et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology 2000 39 632-636
69. Bandoh S, Fujita J, Ohtsuki Y et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. Ann Rheum Dis 2000 59 257-262
70. Ihn H, Asano Y, Kubo M et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. Rheumatology 2002 41 1268-1272
71. Fujita J, Dobashi N, Tokuda M et al. Elevation of cytokeratin 19 fragment in patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. J Rheumatol 1999 26 2377-2382 (Pubitemid 29528976)
72. Gillissen A, Wiechmann V, Jürgens U R. Biomarker in pulmonary disease. Pneumologie 2009 63 439-450
73. Oddis C V. Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000 12 492-497
74. Nawata Y, Kurasawa K, Takabayashi K et al. Corticosteroid resistant interstitial pneumonitis in polymyositis/dermatomyositis: prediction and treatment with cyclosporine. J Rheumatol 1999 26 1527-1533
75. Yoshida T, Koga H, Saitoh F et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999 38 733-738
76. Sakamoto N, Mukae H, Fujii T et al. Nonspecific interstitial pneumonia with poor prognosis associated with amyopathic dermatomyositis. Intern Med 2004 43 838-842
77. Kashiwabara K, Ota K. Rapidly progressive interstitial lung disease in a dermatomyositis patient with high levels of creatine phosphokinase, severe muscle symptoms and positive anti-Jo-1 antibody. Intern Med 2002 41 584-588
78. Tomsic M, Sifrer F. Acute respiratory distress syndrome in a polymyositis patient with the anti-Jo-1 antibody. Wien Klin Wochenschr 2000 112 728-731
79. Bunch T W. Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981 24 45-48
80. Schnabel A, Reuter M, Gross W L. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998 41 1215-1220
81. Yamasaki Y, Yamada H, Yamasaki M et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology 2007 46 124-130
82. Shinohara T, Hidaka T, Matsuki Y et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 1997 36 519-523
83. Dalakas M C. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991 325 1487-1498
84. Sauty A, Rochat T, Schoch O D. et al. Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997 10 2907-2912
85. Sauty A, Rochat T, Schoch O D. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993 329 1993-2000
86. Selva-OCallaghan A, Labrador-Horrillo M, Munoz-Gall X et al. Polymyositis/dermatomyositisassociated lung disease: analysis of a series of 81 patients. Lupus 2005 14 534-542
87. Wilkes M R., Sereika S M., Fertig N et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005 52 2439-2446
88. Oddis C V., Sciurba F C., Elmagd K A., Starzl T E. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999 353 1762-1763
89. Dawson J K., Abernethy V E., Lynch M P. Effective treatment of anti Jo-1 antibodypositive polymyositis with cyclosporin. Br J Rheumatol 1997 36 144-145
90. Majmudar S, Hall H A., Zimmermann B. Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. Clin Rheumatol 2009 15 338-340
91. Mino M, Noma S, Taguchi Y et al. Pulmonary involvement in polymyositis and dermatomyositis: sequential evaluation with CT. AJR Am J Roentgenol 1997 169 83-87
92. Plotz P H., Rider L G., Targoff I N. et al. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann intern Med 1995 122 715-724
93. Miller F W. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin N Amer 1994 20 811-826
94. Fujisawa T, Suda T, Nakamura Y et al. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis. J Rheumatol 2005 32 58-64
95. Haslam P L., Turton C W., Lukoszek A et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980 35 328-339
96. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994 21 1855-1859
97. Callen J P. Myositis and malignancy. Curr Opin Rheumatol 1994 6 590-594
98. Vencovský J, Jarosová K, Machácek S et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000 29 95-102
99. Sem M, Molberg O, Lund M B., Gran J T. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009 48 968-971
100. Hayashi S, Tanaka M, Kobayashi H et al. High-resolution computed tomography characterization of interstitial lung diseases in polymyositis/dermatomyositis. J Rheumatol 2008 35 260-269
101. Atzeni F, Doria A, Carrabba M et al. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007 6 529-536
102. Suzuki Y, Hayakawa H, Miwa S et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/ dermatomyositis. Lung 2009 187 201-206